Edition:
United States

Bayer AG (BAYZF.PK)

BAYZF.PK on OTC Markets Group

126.00USD
18 Aug 2017
Change (% chg)

$0.35 (+0.28%)
Prev Close
$125.65
Open
$126.00
Day's High
$126.00
Day's Low
$126.00
Volume
120
Avg. Vol
2,186
52-wk High
$138.93
52-wk Low
$91.73

BAYZF.PK

Chart for BAYZF.PK

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The... (more)

Overall

Beta: 0.99
Market Cap(Mil.): €88,947.34
Shares Outstanding(Mil.): 826.95
Dividend: 2.70
Yield (%): 2.50

Financials

  BAYZF.PK Industry Sector
P/E (TTM): 20.42 31.59 32.70
EPS (TTM): 5.29 -- --
ROI: 8.69 15.32 14.88
ROE: 16.39 16.34 16.12

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Aug 18 2017

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Aug 18 2017

Bayer, J&J win third U.S. trial over Xarelto bleeding risk

Aug 18 A federal jury has cleared Bayer AG and Johnson & Johnson of liability in the third case to go to trial out of thousands of lawsuits claiming the drugmakers' blood thinner Xarelto led to severe internal bleeding.

Aug 18 2017

Plaintiff in Xarelto trial hits back at Bayer's motion for judgment

A Mississippi woman who said she developed severe internal bleeding after taking Bayer AG and Johnson & Johnson's blood thinner Xarelto asked a federal court on Thursday to dismiss a motion by the drugmakers for judgment as a matter of law.

Aug 17 2017

EU mergers and takeovers (Aug 16)

BRUSSELS, Aug 16 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Aug 16 2017

EU mergers and takeovers (Aug 11)

BRUSSELS, Aug 11 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Aug 11 2017

BRIEF-Bayer and SICIT 2000 sign exclusive distribution agreement‍​

* BAYER AND SICIT 2000 SIGN EXCLUSIVE DISTRIBUTION AGREEMENT‍​

Aug 11 2017

Regeneron beats profit view, to end antibody deal with Sanofi

Regeneron Pharmaceuticals Inc reported a much better-than-expected quarterly profit on strong demand for its flagship Eylea drug and said it would end one of its agreements with France's Sanofi SA to develop antibodies by the end of the year.

Aug 03 2017

UPDATE 4-Regeneron beats profit view, to end antibody deal with Sanofi

* Shares close down 2 pct on plans to scrap antibody deal (Adds details about Sanofi antibody deal, Sanofi and analyst comments, updates shares)

Aug 03 2017

EU mergers and takeovers (Aug 3)

BRUSSELS, Aug 3 The following are mergers under review by the European Commission and a brief guide to the EU merger process:

Aug 03 2017

Earnings vs. Estimates